FDA Approves AstraZeneca’s Kidney Disease Treatment
FDA has approved AstraZeneca’s Farxiga (dapagliflozin) for treating chronic kidney disease in the United States.
AstraZeneca announced on April 30, 2021 that its sodium-glucose cotransporter 2 (SGLT2) inhibitor, Farxiga (dapagliflozin), was approved by FDA for use in the United States to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression.
The approval was based in positive results from the DAPA-CKD Phase III trial, which showed that Farxiga, in combination with an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, reduced the relative risk of worsening of renal function, onset of ESKD, risk of CV, and renal death by 39%, AstraZeneca said in a company press release. The drug also underwent a DECLARE-TIMI 58 Phase III trial which demonstrated that Farxiga is also likely to be effective in patients with less advanced CKD.
“Today’s approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years,” said Mene Pangalos, executive vice-president, BioPharmaceuticals R&D, AstraZeneca. “We’ve shown impressive efficacy for Farxiga in type-2 diabetes, heart failure with reduced ejection fraction and, most recently, chronic kidney disease and we are thrilled to be able to bring this medicine to millions of patients in the US.”
Source: AstraZeneca
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
